Dr. Schulman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Route 112 Bldg 4 Ste 101
Port Jefferson Station, NY 11776Phone+1 631-751-3000Fax+1 631-509-6559
Education & Training
- Zucker School of Medicine at Hofstra/NorthwellFellowship, Hematology and Medical Oncology, 1978 - 1979
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1977 - 1978
- Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 1975 - 1977
- Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1974 - 1975
- SUNY Upstate Medical UniversityClass of 1974
Certifications & Licensure
- CT State Medical License 2024 - 2025
- NY State Medical License 1975 - 2025
- PA State Medical License 2022 - 2024
- FL State Medical License 2021 - 2023
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 18 citationsPhase I Trial of Weekly and Twice-Weekly Bortezomib with Rituximab, Cyclophosphamide, and Prednisone in Relapsed or Refractory Non–Hodgkin LymphomaJohn F. Gerecitano, Carol S. Portlock, Paul A. Hamlin, Craig H. Moskowitz, Ariela Noy
Clinical Cancer Research. 2011-04-15 - 14 citationsBortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myel...Heather Landau, Neeta Pandit-Taskar, Hani Hassoun, Adam D. Cohen, Alex Lesokhin
Leukemia & Lymphoma. 2012-02-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: